Abstract
Human oxalated plasma stored at 4° C. until the prothrombin time is increased beyond 60 sec. is a reliable medium for assaying labile factor (factor V) because its response to added labile factor corresponds quantitatively to that of plasma from patients with congenital deficiency of this factor. Such an agreement is not obtained with plasma stored at 37°C. The stability of labile factor is closely associated with ionized calcium. The addition of thrombin to fresh oxalated plasma causes an apparent hyperactivity of labile factor, but this is completely removed by adsorption with Ca3(PO)2. Oxalated plasma when adsorbed with Ca3(PO4)2 before treatment with thrombin does not develop this adventitious activity, nor does it occur in stored plasma treated with thrombin. The seemingly high labile factor activity in serum can be explained by the activation of this factor which is independent of labile factor but acts synergistically with it. The true labile factor concentration can be determined only after the accelerator is removed by adsorption with Ca3(PO4)2. A close agreement between the consumption of prothrombin and the loss of labile factor during clotting is observed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ALEXANDER B., GOLDSTEIN R., LANDWEHR G. The prothrombin conversion accelerator of serum (SPCA): its partial purification and its properties compared with serum AC-globulin. J Clin Invest. 1950 Jul;29(7):881–895. doi: 10.1172/JCI102322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Alexander B., De Vries A., Addelson E. HUMAN PROTHROMBIN: QUANTITATIVE STUDIES ON THE PLASMA LABILE FACTOR AND THE RESTORATIVE EFFECTS OF NORMAL, HYPOFI-BRINOGENEMIC, AND HEMOPHILIC PLASMA ON THE PROTHROMBIN OF STORED PLASMA. J Clin Invest. 1949 Jan;28(1):24–31. doi: 10.1172/JCI102048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Alexander B., de Vries A., Goldstein R., Landwehr G. A Prothrombin Conversion Accelerator in Serum. Science. 1949 May 27;109(2839):545–545. doi: 10.1126/science.109.2839.545. [DOI] [PubMed] [Google Scholar]
- CONSOLAZIO C. F., SARGENT F., HUSSEY C. V., QUICK A. F., STEFANINI M., CONSOAZIO C. F., SARGENT F., 2nd Effect of sodium citrate and heparin on I removal of calcium from blood and serum by amberlite. J Biol Chem. 1950 May;184(1):105–108. [PubMed] [Google Scholar]
- DIDISHEIM P., HATTORI K., LEWIS J. H. Hematologic and coagulation studies in various animal species. J Lab Clin Med. 1959 Jun;53(6):866–875. [PubMed] [Google Scholar]
- DOUGLAS A. S. Factor-V consumption during blood coagulation. Br J Haematol. 1956 Apr;2(2):153–159. doi: 10.1111/j.1365-2141.1956.tb06823.x. [DOI] [PubMed] [Google Scholar]
- WOLF P. A modification for routine laboratory use of Stefanini's method of estimating factor V activity in human oxalated plasma. J Clin Pathol. 1953 Feb;6(1):34–38. doi: 10.1136/jcp.6.1.34. [DOI] [PMC free article] [PubMed] [Google Scholar]